csirt@kutim:~/threat-intel/cve/CVE-2023-27533

Katalog CVE

CVSS 8.8 · High EPSS 2,0%

Kerentanan Failure to Sanitize Special Elements into a Different Plane (Special Element Injection) pada haxx curl, fedoraproject fedora +7 lainnya. Skor CVSS 3.1 8.8 (High) menurut NVD.

Deskripsi (NVD)

A vulnerability in input validation exists in curl <8.0 during communication using the TELNET protocol may allow an attacker to pass on maliciously crafted user name and "telnet options" during server negotiation. The lack of proper input scrubbing allows an attacker to send content or perform option negotiation without the application's intent. This vulnerability could be exploited if an application allows user input, thereby enabling attackers to execute arbitrary code on the system.

Rincian

Terbit di NVD
30 Maret 2023
Terakhir diubah
17 Juni 2026
Status NVD
Modified
CVSS 3.1
8.8 (High), sumber NVD
CVSS:3.1/AV:N/AC:L/PR:N/UI:R/S:U/C:H/I:H/A:H · uraikan di kalkulator
Jenis kelemahan (CWE)
CWE-75: Failure to Sanitize Special Elements into a Different Plane (Special Element Injection)
CWE-74: Improper Neutralization of Special Elements in Output Used by a Downstream Component ('Injection')
EPSS (30 hari)
2,0% peluang dieksploitasi; lebih tinggi dari 80,1% CVE lain

Produk dan versi terdampak

VendorProdukVersi terdampak
haxx curl Versi 7.0.0 hingga 7.881
fedoraproject fedora Versi 36
netapp active iq unified manager Semua versi
netapp clustered data ontap Versi 9.0
netapp h300s firmware Semua versi
netapp h500s firmware Semua versi
netapp h700s firmware Semua versi
netapp h410s firmware Semua versi
splunk universal forwarder Versi 8.2.0 hingga sebelum 8.2.12
splunk universal forwarder Versi 9.0.0 hingga sebelum 9.0.6
splunk universal forwarder Versi 9.1.0

> Data dari konfigurasi CPE di NVD.

Referensi dan perbaikan

Sumber: NVD · CVE.org · EPSS. Halaman ini disusun otomatis dari data tersebut; pembaruan terakhir 5 Okt 2026, 20:10 WITA. Kalau sistem di Perangkat Daerah memakai produk ini dan butuh bantuan, laporkan lewat kanal pelaporan.